Blerina Shkodra

Dr. Blerina Shkodra

Institute of Organic Chemistry and Macromolecular Chemistry
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Blerina ShkodraBlerina Shkodra
Blerina Shkodra
CGC. Grune
C. Grune
ATA. Traeger
A. Traeger
AVA. Vollrath
A. Vollrath
SSS. Schubert
S. Schubert
Ulrich SchubertUlrich Schubert
Ulrich Schubert

22 January 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ATAnja Traeger
Anja Traeger
SVSusanna Voelker
Susanna Voelker
Blerina ShkodraBlerina Shkodra
Blerina Shkodra
CKChristian Kretzer
Christian Kretzer
SSStephanie Schubert
Stephanie Schubert
OWOliver Werz
Oliver Werz

31 July 2021 in Polymers
Verified
Journal Article
Open access
PDF file
AVAntje Vollrath
Antje Vollrath
CKChristian Kretzer
Christian Kretzer
BBBaerbel Beringer-Siemers
Baerbel Beringer-Siemers
Blerina ShkodraBlerina Shkodra
Blerina Shkodra
JCJustyna A. Czaplewska
Justyna A. Czaplewska
Ulrich SchubertUlrich Schubert
Ulrich Schubert
Seven polycaprolactones (PCL) with constant hydrophobicity but a varying degree of crystallinity prepared from the constitutional isomers ε-caprolactone (εCL) and δ-caprolactone (δCL) were utilized to formulate nanoparticles (NPs). The aim was to investigate the effect of the crystallinity of the bulk polymers on the enzymatic degradation of the particles. Furthermore, their efficiency to encapsulate the hydrophobic anti-inflammatory drug BRP-187 and the final in vitro performance of the resulting NPs were evaluated. Initially, high-throughput nanoprecipitation was employed for the εCL and δCL homopolymers to screen and establish important formulation parameters (organic solvent, polymer and surfactant concentration). Next, BRP-187-loaded PCL nanoparticles were prepared by batch nanoprecipitation and characterized using dynamic light scattering, scanning electron microscopy and UV-Vis spectroscopy to determine and to compare particle size, polydispersity, zeta potential, drug loading as well as the apparent enzymatic degradation as a function of the copolymer composition. Ultimately, NPs were examined for their potency in vitro in human polymorphonuclear leukocytes to inhibit the BRP-187 target 5-lipoxygenase-activating protein (FLAP). It was evident by Tukey’s multi-comparison test that the degree of crystallinity of copolymers directly influenced their apparent enzymatic degradation and consequently their efficiency to inhibit the drug target.

18 November 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Blerina ShkodraBlerina Shkodra
Blerina Shkodra
Adrian Tibor PressAdrian Tibor Press
Adrian Tibor Press
AVAntje Vollrath
Antje Vollrath
Ivo NischangIvo Nischang
Ivo Nischang
SSStephanie Schubert
Stephanie Schubert
Ulrich SchubertUlrich Schubert
Ulrich Schubert
Bisindolylmaleimide I (BIM-I) is a competitive pan protein kinase C inhibitor with anti-inflammatory and anti-metastatic properties, suggested to treat inflammatory diseases and various cancer entities. However, despite its therapeutic potential, BIM-I has two major drawbacks, i.e., it has a poor water solubility, and it binds the human ether-à-go-go-related gene (hERG) ion channels, potentially causing deadly arrhythmias. In this case, a targeted delivery of BIM-I is imperative to minimize peripheral side effects. To circumvent these drawbacks BIM-I was encapsulated into nanoparticles prepared from poly(lactic-co-glycolic acid) (PLGA) functionalized by the near-infrared dye DY-635. DY-635 served as an active targeting moiety since it selectively binds the OATP1B1 and OATP1B3 transporters that are highly expressed in liver and cancer cells. PLGA-DY-635 (BIM-I) nanoparticles were produced by nanoprecipitation and characterized using dynamic light scattering, analytical ultracentrifugation, and cryogenic transmission electron microscopy. Particle sizes were found to be in the range of 20 to 70 nm, while a difference in sizes between the drug-loaded and unloaded particles was observed by all analytical techniques. In vitro studies demonstrated that PLGA-DY-635 (BIM-I) NPs prevent the PKC activation efficiently, proving the efficacy of the inhibitor after its encapsulation, and suggesting that BIM-I is released from the PLGA-NPs. Ultimately, our results present a feasible formulation strategy that improved the cytotoxicity profile of BIM-I and showed a high cellular uptake in the liver as demonstrated in vivo by intravital microscopy investigations.

1 January 2020
Verified
Book Chapter
Closed access
Blerina ShkodraBlerina Shkodra
Blerina Shkodra
AVAntje Vollrath
Antje Vollrath
USUlrich S. Schubert
Ulrich S. Schubert
SSStephanie Schubert
Stephanie Schubert

30 November 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
TKTobias Kammann
Tobias Kammann
JHJessica Hoff
Jessica Hoff
IYIlknur Yildirim
Ilknur Yildirim
Blerina ShkodraBlerina Shkodra
Blerina Shkodra
TMTina Müller
Tina Müller
Adrian Tibor PressAdrian Tibor Press
Adrian Tibor Press
Cholesterol is highly abundant within all human body cells and modulates critical cellular functions related to cellular plasticity, metabolism, and survival. The cholesterol-binding toxin pneumolysin represents an essential virulence factor of Streptococcus pneumoniae in establishing pneumonia and other pneumococcal infections. Thus, cholesterol scavenging of pneumolysin is a promising strategy to reduce S. pneumoniae induced lung damage. There may also be a second cholesterol-dependent mechanism whereby pneumococcal infection and the presence of pneumolysin increase hepatic sterol biosynthesis. Here we investigated a library of polymer particles varying in size and composition that allow for the cellular delivery of cholesterol and their effects on cell survival mechanisms following pneumolysin exposure. Intracellular delivery of cholesterol by nanocarriers composed of Eudragit E100–PLGA rescued pneumolysin-induced alterations of lipid homeostasis and enhanced cell survival irrespective of neutralization of pneumolysin.